GSK, Amgen want SCOTUS to protect genus claims

Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme (MSD) in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

GSK claims Amgen v Sanofi decision “threatens” innovation

29 April 2021 GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”

Americas

SCOTUS weighs future of assignor estoppel

11 January 2021 The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.

Americas

Fed Circuit affirms GSK $107m patent loss

20 November 2020 The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

GSK, Amgen want SCOTUS to protect genus claims

More on this story

Editor's picks

Editor's picks

More features